PhaseBio Pharmaceuticals Inc

$ Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000116924522000028 Filed on March 24, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.80M	$41.80M	$28.10M
YoY Change	48.75%	48.65%	-62.03%
Cash & Equivalents	$41.80M	$41.80M	$28.12M
Short-Term Investments
Other Short-Term Assets	$6.984M	$6.984M	$12.00M
YoY Change	-41.8%	-41.95%	233.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables			$0.00
Total Short-Term Assets	$48.78M	$48.78M	$40.15M
YoY Change	21.51%	21.5%	-49.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.23M	$11.70M	$8.224M
YoY Change	24.39%	15.26%	327.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$57.00K	$57.00K	$57.00K
YoY Change	0.0%	-5.0%	78.13%
Total Long-Term Assets	$11.76M	$11.76M	$10.21M
YoY Change	15.16%	15.14%	178.07%
TOTAL ASSETS
Total Short-Term Assets	$48.78M	$48.78M	$40.15M
Total Long-Term Assets	$11.76M	$11.76M	$10.21M
Total Assets	$60.54M	$60.54M	$50.36M
YoY Change	20.22%	20.21%	-38.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.57M	$12.57M	$3.674M
YoY Change	242.13%	242.51%	25.78%
Accrued Expenses	$8.353M	$8.353M	$5.931M
YoY Change	40.84%	40.86%	86.51%
Deferred Revenue	$1.547M		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.413M	$5.413M	$5.355M
YoY Change	1.08%	0.99%	125.19%
Total Short-Term Liabilities	$27.88M	$27.88M	$14.96M
YoY Change	86.38%	86.38%	76.44%
LONG-TERM LIABILITIES
Long-Term Debt	$1.359M	$1.359M	$6.773M
YoY Change	-79.94%	-79.93%	-45.05%
Other Long-Term Liabilities	$794.0K	$124.3M	$559.0K
YoY Change	42.04%	130.97%	175.37%
Total Long-Term Liabilities	$2.153M	$125.7M	$7.332M
YoY Change	-70.64%	107.41%	-41.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.88M	$27.88M	$14.96M
Total Long-Term Liabilities	$2.153M	$125.7M	$7.332M
Total Liabilities	$153.6M	$153.6M	$75.56M
YoY Change	103.25%	103.25%	235.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$391.8M		-$260.7M
YoY Change	50.27%		60.78%
Common Stock	$48.00K		$29.00K
YoY Change	65.52%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$24.00K		$24.00K
YoY Change	0.0%		0.0%
Treasury Stock Shares	29.97K shares		29.97K shares
Shareholders Equity	-$93.03M	-$93.03M	-$25.20M
YoY Change
Total Liabilities & Shareholders Equity	$60.54M	$60.54M	$50.36M
YoY Change	20.22%	20.21%	-38.96%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001169245
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38697
CY2021	dei	Entity Registrant Name EntityRegistrantName	PhaseBio Pharmaceuticals, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	03-0375697
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Great Valley Parkway
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 30
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Malvern
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19355
CY2021	dei	City Area Code CityAreaCode	610
CY2021	dei	Local Phone Number LocalPhoneNumber	981-6500
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	PHAS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	168900000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48690590	shares
CY2021	dei	Auditor Firm AuditorFirmId	185
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41800000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28122000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6984000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12027000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	48784000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	40149000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10230000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8224000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1469000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1927000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57000	USD
CY2021Q4	us-gaap	Assets Assets	60540000	USD
CY2020Q4	us-gaap	Assets Assets	50357000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5413000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5355000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1547000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12570000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3674000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8353000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5931000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27883000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14960000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1359000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6773000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1073000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1548000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7622000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	114843000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	51719000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	794000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	559000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	153574000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	75559000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48220557	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48190590	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29471854	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29441887	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	48000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	29000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	29967	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	29967	shares
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	24000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	24000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	298736000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	235516000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-391794000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-260723000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-93034000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-25202000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60540000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50357000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10831000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	320000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	102107000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72088000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16086000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13088000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	118193000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	85176000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-107362000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-84856000	USD
CY2021	phas	Gain Loss From Remeasurement Of Derivative Liability GainLossFromRemeasurementOfDerivativeLiability	-21182000	USD
CY2020	phas	Gain Loss From Remeasurement Of Derivative Liability GainLossFromRemeasurementOfDerivativeLiability	-12507000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	14000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	237000	USD
CY2021	us-gaap	Interest Expense InterestExpense	947000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1445000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-22109000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13709000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-129471000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-98565000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-131071000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-98565000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.98
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.98
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.39
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.39
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43918996	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43918996	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29056304	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29056304	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	59978000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	7925000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2942000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	186000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	95000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2237000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-98565000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-25202000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60241000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	336000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	394000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2268000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-131071000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-93034000	USD
CY2021	us-gaap	Profit Loss ProfitLoss	-131071000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-98565000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1793000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	508000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2268000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2237000	USD
CY2021	phas	Gain Loss From Remeasurement Of Derivative Liability GainLossFromRemeasurementOfDerivativeLiability	-21182000	USD
CY2020	phas	Gain Loss From Remeasurement Of Derivative Liability GainLossFromRemeasurementOfDerivativeLiability	-12507000	USD
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	304000	USD
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	491000	USD
CY2021	phas	Noncashor Part Noncash Researchand Development Expense NoncashorPartNoncashResearchandDevelopmentExpense	28740000	USD
CY2020	phas	Noncashor Part Noncash Researchand Development Expense NoncashorPartNoncashResearchandDevelopmentExpense	27027000	USD
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	100000	USD
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1233000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7505000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8375000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9010000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	974000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3684000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1906000	USD
CY2021	phas	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	9169000	USD
CY2020	phas	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47416000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59957000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2679000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1312000	USD
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	100000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2679000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1412000	USD
CY2021	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	-8184000	USD
CY2020	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	-15169000	USD
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	60354000	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2942000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	40000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	199000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	394000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	95000	USD
CY2021	phas	Proceeds From Repayment Of Employee Stock Purchase Plans ProceedsFromRepaymentOfEmployeeStockPurchasePlans	336000	USD
CY2020	phas	Proceeds From Repayment Of Employee Stock Purchase Plans ProceedsFromRepaymentOfEmployeeStockPurchasePlans	186000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5455000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2727000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	63773000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15466000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13678000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45903000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28122000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74025000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41800000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28122000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	517000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	954000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	576000	USD
CY2021	phas	Issuanceof Stockand Warrantsfor Derivative Instruments IssuanceofStockandWarrantsforDerivativeInstruments	0	USD
CY2020	phas	Issuanceof Stockand Warrantsfor Derivative Instruments IssuanceofStockandWarrantsforDerivativeInstruments	7925000	USD
CY2021	phas	Capital Expenditures Incurred But Not Yet Paid Incurring Development Derivative Liability CapitalExpendituresIncurredButNotYetPaidIncurringDevelopmentDerivativeLiability	2482000	USD
CY2020	phas	Capital Expenditures Incurred But Not Yet Paid Incurring Development Derivative Liability CapitalExpendituresIncurredButNotYetPaidIncurringDevelopmentDerivativeLiability	4941000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1378000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-391800000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41800000	USD
CY2021Q4	phas	Working Capital WorkingCapital	20900000	USD
CY2021	phas	Aggregate Offering Amount Of Common Stock Preferred Stock Debt Securities And Warrants AggregateOfferingAmountOfCommonStockPreferredStockDebtSecuritiesAndWarrants	200000000	USD
CY2020Q1	us-gaap	Preferred Units Offering Costs PreferredUnitsOfferingCosts	200000000	USD
CY2021Q4	phas	Aggregate Offering Price Of Common Stock Preferred Stock Debt Securities And Warrants Remaining AggregateOfferingPriceOfCommonStockPreferredStockDebtSecuritiesAndWarrantsRemaining	132600000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of the development derivative liability, the clinical trial accruals, and the deferral and recognition of revenue under the exclusive sublicense agreement (the "Alfasigma Sublicense") entered into with Alfasigma S.p.A ("Alfasigma"). Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains certain deposits in federally insured financial institutions in excess of federally insured limits. The Company could experience losses on the money market funds in the future.</span></div>
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7138078	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6556525	shares
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14150000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10350000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3920000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2126000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10230000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8224000	USD
CY2021	us-gaap	Depreciation Depreciation	1800000	USD
CY2020	us-gaap	Depreciation Depreciation	500000	USD
CY2021Q4	phas	Accrued Clinical And Related Costs Current AccruedClinicalAndRelatedCostsCurrent	3985000	USD
CY2020Q4	phas	Accrued Clinical And Related Costs Current AccruedClinicalAndRelatedCostsCurrent	2753000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2850000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2260000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	38000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	69000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1005000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	459000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	475000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	390000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8353000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5931000	USD
CY2010Q1	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	three years
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.059
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	555000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	419000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	279000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	283000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	215000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1751000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	202000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1549000	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	600000	USD
CY2020Q1	us-gaap	Preferred Units Offering Costs PreferredUnitsOfferingCosts	200000000	USD
CY2020Q1	us-gaap	Preferred Units Offering Costs PreferredUnitsOfferingCosts	200000000	USD
CY2021Q4	phas	Aggregate Offering Price Of Common Stock Preferred Stock Debt Securities And Warrants Remaining AggregateOfferingPriceOfCommonStockPreferredStockDebtSecuritiesAndWarrantsRemaining	132600000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.46
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.20
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2268000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2237000	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Second And Third Year PurchaseObligationDueInSecondAndThirdYear	14000000	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	37000000	USD
CY2021Q1	phas	Purchase Obligation To Be Paid Year Five Through Eleven PurchaseObligationToBePaidYearFiveThroughEleven	48000000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1600000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1600000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-27189000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20699000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7065000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-6823000	USD
CY2021	phas	Income Tax Reconciliation Of Permanent Items IncomeTaxReconciliationOfPermanentItems	348000	USD
CY2020	phas	Income Tax Reconciliation Of Permanent Items IncomeTaxReconciliationOfPermanentItems	8000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	174000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	215000	USD
CY2021	us-gaap	Income Tax Reconciliation Deductions Medicare Prescription Drug Benefit Subsidy IncomeTaxReconciliationDeductionsMedicarePrescriptionDrugBenefitSubsidy	1827000	USD
CY2020	us-gaap	Income Tax Reconciliation Deductions Medicare Prescription Drug Benefit Subsidy IncomeTaxReconciliationDeductionsMedicarePrescriptionDrugBenefitSubsidy	2544000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2489000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	863000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1125000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	785000	USD
CY2021	phas	Effective Income Tax Rate Reconciliation Change In State Rate Amount EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount	-910000	USD
CY2020	phas	Effective Income Tax Rate Reconciliation Change In State Rate Amount EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount	-74000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	36284000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	28090000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1329000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1757000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1600000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	70903000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	12061000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	8662000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	921000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	936000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51398000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	31000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	43000	USD
CY2021Q4	phas	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	411000	USD
CY2020Q4	phas	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	562000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	30491000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	16700000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	615000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	628000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	115433000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	78929000	USD
CY2021Q4	phas	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	390000	USD
CY2020Q4	phas	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	540000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	694000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	324000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1084000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	864000	USD
CY2021Q4	phas	Deferred Tax Assets Gross Before Valuation Allowance DeferredTaxAssetsGrossBeforeValuationAllowance	114349000	USD
CY2020Q4	phas	Deferred Tax Assets Gross Before Valuation Allowance DeferredTaxAssetsGrossBeforeValuationAllowance	78065000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	114349000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78065000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	114300000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78100000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	36300000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28100000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3345000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2560000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1236000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	871000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	55000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	86000	USD
CY2021	phas	Unrecognized Tax Benefits Expiration UnrecognizedTaxBenefitsExpiration	0	USD
CY2020	phas	Unrecognized Tax Benefits Expiration UnrecognizedTaxBenefitsExpiration	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4636000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3345000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3300000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4600000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	200000	USD

Files In Submission

Name	View Source	Status
0001169245-22-000028-index-headers.html	Edgar Link	pending
0001169245-22-000028-index.html	Edgar Link	pending
0001169245-22-000028.txt	Edgar Link	pending
0001169245-22-000028-xbrl.zip	Edgar Link	pending
ex-321xphas10xk2021.htm	Edgar Link	pending
ex-322xphas10xk2021.htm	Edgar Link	pending
ex1025-biovectra_amendment.htm	Edgar Link	pending
ex103-2018equityincentivep.htm	Edgar Link	pending
ex106-2022inducementplanxf.htm	Edgar Link	pending
ex107-phasebioxnonxemploye.htm	Edgar Link	pending
ex109-phasebioxamendedxres.htm	Edgar Link	pending
ex231-10xk2021consentofkpm.htm	Edgar Link	pending
ex311-phas10xk2021.htm	Edgar Link	pending
ex312-phas10xk2021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
phas-20211231.htm	Edgar Link	pending
phas-20211231.xsd	Edgar Link	pending
phas-20211231_cal.xml	Edgar Link	unprocessable
phas-20211231_def.xml	Edgar Link	unprocessable
phas-20211231_g1.jpg	Edgar Link	pending
phas-20211231_g2.jpg	Edgar Link	pending
phas-20211231_htm.xml	Edgar Link	completed
phas-20211231_lab.xml	Edgar Link	unprocessable
phas-20211231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

PhaseBio Pharmaceuticals Inc

2021 Q4 Form 10-K Financial Statement

#000116924522000028 Filed on March 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission